These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 23356491

  • 1. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.
    Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ.
    Br J Haematol; 2013 Apr; 161(1):76-86. PubMed ID: 23356491
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).
    Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ.
    J Clin Oncol; 2013 Feb 20; 31(6):684-91. PubMed ID: 23182987
    [Abstract] [Full Text] [Related]

  • 3. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
    Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ.
    J Clin Oncol; 2015 Jun 10; 33(17):1936-42. PubMed ID: 25897153
    [Abstract] [Full Text] [Related]

  • 4. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
    Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B.
    Cochrane Database Syst Rev; 2017 May 25; 5(5):CD007941. PubMed ID: 28541603
    [Abstract] [Full Text] [Related]

  • 5. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
    Paoli D, Rizzo F, Fiore G, Pallotti F, Pulsoni A, Annechini G, Lombardo F, Lenzi A, Gandini L.
    Hum Reprod; 2016 Feb 25; 31(2):263-72. PubMed ID: 26705149
    [Abstract] [Full Text] [Related]

  • 6. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi.
    J Clin Oncol; 2005 Dec 20; 23(36):9198-207. PubMed ID: 16172458
    [Abstract] [Full Text] [Related]

  • 7. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, Akria L, Tadmor T, Filanovsky K, Abadi U, Kagna O, Ruchlemer R, Abdah-Bortnyak R, Goldschmidt N, Epelbaum R, Horowitz NA, Lavie D, Ben-Yehuda D, Shpilberg O, Paltiel O.
    Br J Haematol; 2017 Sep 20; 178(5):709-718. PubMed ID: 28589704
    [Abstract] [Full Text] [Related]

  • 8. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.
    Ezzat HM, Cheung MC, Hicks LK, Boro J, Montaner JS, Lima VD, Harris M, Leitch HA.
    Leuk Lymphoma; 2012 Dec 20; 53(12):2390-6. PubMed ID: 22642935
    [Abstract] [Full Text] [Related]

  • 9. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C.
    J Clin Oncol; 2012 Nov 20; 30(33):4117-23. PubMed ID: 23045592
    [Abstract] [Full Text] [Related]

  • 10. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
    Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N.
    J Clin Oncol; 2016 Jun 10; 34(17):2028-36. PubMed ID: 27114593
    [Abstract] [Full Text] [Related]

  • 11. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M.
    J Clin Oncol; 2011 Nov 10; 29(32):4227-33. PubMed ID: 21990405
    [Abstract] [Full Text] [Related]

  • 12. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
    Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, Diehl V, Borchmann P, Engert A, von Tresckow B.
    Lancet Haematol; 2021 Apr 10; 8(4):e278-e288. PubMed ID: 33770483
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of standard BEACOPP regimen versus ABVD regimen for treatment of advanced Hodgkin's lymphoma.
    Lin N, He C, Zhang Q, Hong X, Liu L, Yang S, Su H, Li X, Dai X, Li Y, Zhu J.
    J Cancer Res Ther; 2024 Aug 01; 20(4):1258-1264. PubMed ID: 39206988
    [Abstract] [Full Text] [Related]

  • 14. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
    Filatova LV, Plotnikova AA, Gershanovich ML, Semiglazova TIu.
    Vopr Onkol; 2013 Aug 01; 59(2):59-65. PubMed ID: 23814851
    [Abstract] [Full Text] [Related]

  • 15. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
    Koontz MZ, Horning SJ, Balise R, Greenberg PL, Rosenberg SA, Hoppe RT, Advani RH.
    J Clin Oncol; 2013 Feb 10; 31(5):592-8. PubMed ID: 23295809
    [Abstract] [Full Text] [Related]

  • 16. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM.
    J Clin Oncol; 1998 Jan 10; 16(1):19-26. PubMed ID: 9440718
    [Abstract] [Full Text] [Related]

  • 17. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
    Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A.
    Br J Haematol; 2016 Mar 10; 172(6):879-88. PubMed ID: 26763986
    [Abstract] [Full Text] [Related]

  • 18. Long-term follow-up of survival in Hodgkin's lymphoma.
    Canellos GP, Niedzwiecki D, Johnson JL.
    N Engl J Med; 2009 Dec 10; 361(24):2390-1. PubMed ID: 20007568
    [No Abstract] [Full Text] [Related]

  • 19. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.
    Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P.
    Blood; 2016 May 05; 127(18):2189-92. PubMed ID: 26834240
    [Abstract] [Full Text] [Related]

  • 20. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.
    Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M, European Organisation for Research and Treatment of Cancer Lymphoma Group, and, Groupe d'Étude des Lymphomes de l'Adulte.
    Eur J Cancer; 2017 Aug 05; 81():45-55. PubMed ID: 28601705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.